|
|
 |
|
CEPH: Cephalon Inc - Stock News |
Enter Ticker:
|
|
| Nov 20, 2009 |
Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group |
| Nov 17, 2009 |
The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018 |
| Nov 10, 2009 |
Conference Calls Today: 12-1:40 P.M. EDT |
| Nov 05, 2009 |
Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma |
| Nov 04, 2009 |
Cephalon, Inc. to Webcast R&D Day |
| Nov 03, 2009 |
Dr. Stockpick Announces Daily Stock Watch - XOMA, DDRX, CEPH |
| Nov 02, 2009 |
Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder |
| Oct 27, 2009 |
Cephalon Revises Guidance with Revenue Below Estimates |
| Oct 27, 2009 |
Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009 |
| Oct 27, 2009 |
MONSTERSTOX.COM: Monsterstox.com : Cephalon, Inc. (Nasdaq: CEPH) |
| Oct 27, 2009 |
Cephalon Appoints Bob Repella as Senior Vice President of U.S. Pharmaceutical Operations |
| Oct 27, 2009 |
Conference Calls Today: 5-6 P.M. EDT |
| Oct 26, 2009 |
Cephalon (CEPH) NewsBite - CEPH Is Moving Higher Today Ahead Of Q3 Earnings Release |
| Oct 26, 2009 |
xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts October 26, 2009 : ICGN, LCUT, CEPH and MANH |
| Oct 26, 2009 |
MONSTERSTOX.COM: Monsterstox.com : Cephalon, Inc. (Nasdaq: CEPH) |
| |
| ZACKS COMMENTARY FOR CEPH |
| Nov 20, 2009 | Zacks Blog: Biogen's Rituxan Label Expansion Delayed | | Nov 05, 2009 | Zacks Blog: King Beats, but Earnings Down | | Oct 29, 2009 | Zacks Equity Research: Report for CEPH | | Oct 28, 2009 | Zacks Blog: Cephalon Beats, Provides Outlook | | Oct 23, 2009 | Zacks Blog: CEPH’s Nuvigil Faces Generic Threat | | Oct 01, 2009 | Zacks Blog: Campath Meets Primary Endpoint | | Sep 29, 2009 | Zacks Blog: Nuvigil Granted Priority Review | | Sep 17, 2009 | Zacks Blog: Encouraging Data for Pixantrone | | Sep 08, 2009 | Zacks Blog: Cell Therapeutics Fails to Impress | | Aug 12, 2009 | Zacks Blog: Cephalon Completes Acquisition | | Aug 07, 2009 | Zacks Blog: Zacks Bull and Bear of the Day Highlights: Baxter International, The Corporate Executive Board, King Pharmaceuticals, Inc., ZymoGenetics and Cephalon | | Aug 06, 2009 | Zacks Blog: King Beats Zacks Estimates |
|
|
Sponsored Links 
-0.10